Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR -0.35%67 EV-to-EBIT is 53.08 as of Jul. 29, 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 67/100 and a GF Value™ of kr2.36 (Modestly Overvalued). Among 468 Medical Devices & Instruments companies, Medclair AB ranks worse than 86.97% on this metric.
The historical rank and industry rank for Medclair AB's EV-to-EBIT or its related term are showing as below:
NGM:MCLR'
s EV-to-EBIT Range Over the Past 10 Years
Min: -170.61 Med: -19.7 Max: 280.54
Current: 53.07
During the past 11 years, the highest EV-to-EBIT of Medclair AB was 280.54. The lowest was -170.61. And the median was -19.70.
NGM:MCLR's EV-to-EBIT is ranked worse than 86.97% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 18.695
vs NGM:MCLR: 53.07
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medclair AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr194.08 Mil.
Medclair AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB EV-to-EBIT Related Terms
Medclair AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medclair AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medclair AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medclair AB's EV-to-EBIT falls into.
Medclair AB's current Enterprise Value is kr262.69 Mil.
Medclair AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a EV-to-EBIT of 53.08 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medclair AB and its competitors. According to the industry distribution chart, Medclair AB ranks #407 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 87%.
Is Medclair AB's EV-to-EBIT too high?
Medclair AB's current EV-to-EBIT is 53.08. The Medical Devices & Instruments industry median EV-to-EBIT is 18.70. Medclair AB's value of 53.08 is 183.9% above this industry median. Based on the distribution chart, Medclair AB ranks #407 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medclair AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #407 out of 468 companies for EV-to-EBIT. This places Medclair AB in the lower half of its industry. The industry median EV-to-EBIT is 18.70. Medclair AB's value of 53.08 is 183.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.70, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current EV-to-EBIT of 53.08 is 183.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current EV-to-EBIT is 53.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.36, compared to a current price of kr2.88 — trading 22% above its estimated fair value. The current EV-to-EBIT is 53.08 and 183.9% above the Medical Devices & Instruments industry median of 18.70. Medclair AB's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current EV-to-EBIT is 53.08 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.88 is trading 22% above its estimated GF Value™ of kr2.36.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
EV-to-EBIT: 53.08
GF Value™: kr2.36 vs. price of kr2.88 (22% above fair value)
Industry Position: 183.9% above the Medical Devices & Instruments median (#407 of 468)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
67GF Score
Get the complete analysis for NGM:MCLR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
